Labcorp (LH) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: Setup looks constructive — consensus is a manageable bar after the Q1 beat-and-raise, and the biggest swing factor is whether the BLS quarterly book-to-bill rebounds above 1.0 as management guided, validating the Central Labs growth thesis.

Heading into Q2 2026, Labcorp faces a reasonable consensus bar: revenue of ~$3.71B (+5.2% YoY) and adjusted EPS of ~$4.78, both achievable given the momentum management described exiting Q1.

Management's tone on the Q1 call was notably confident — CEO Adam Schechter stated he feels "good about where we are" and "like we've got momentum as we move into the second quarter," and the company raised full-year guidance at the midpoint for both revenue and EPS.

Estimate revisions have been broadly stable since the Q1 print, with Q2 consensus revenue essentially unchanged at ~$3.71B vs. the ~$3.71B baseline set 5 days post-Q1 earnings, suggesting the street has largely digested the raise without adding further cushion.

The stock has rallied ~+19.6% since the April 30 earnings date (vs. XLV +13.9%), reflecting a re-rating on the beat-and-raise and improving sentiment around PAMA delay through 2026, but the multiple remains compressed relative to history, leaving room for further upside if Q2 delivers.

The key wildcard is the BLS quarterly book-to-bill: management explicitly guided for sequential improvement from Q1's 0.94x, and a print above 1.0x would validate the Central Labs growth story and likely drive the stock higher, while a second consecutive sub-1.0x read would reignite concerns about BLS revenue visibility heading into 2H 2026.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus sets a manageable bar on revenue (~$3.71B, +5.2% YoY) and adjusted EPS (~$4.78, +9.9% YoY). The bigger swing factor is the BLS book-to-bill — a rebound above 1.0x would be the most meaningful positive signal, while Diagnostics organic growth trajectory (consensus ~3.9%) is the key volume read.

Table 1 — Q2 2026 Current Quarter Snapshot

Source: Visible Alpha Consensus and Actuals Data. All consensus figures as of July 29, 2026. Q2 2026 guidance references Q1 2026 earnings call (April 30, 2026). FY 2026 guidance midpoint: revenue growth 5.55%, adjusted EPS $18.025.

Table 2 — Beat/Miss History (Last 8 Quarters) — Top 2 KPIs: Revenue & Adjusted EPS

Pattern: LH has beaten adjusted EPS consensus in all 8 of the last 8 quarters; revenue beats are more mixed (6 of 8), with the two misses driven by weather (Q1 2025) and softer Q4 2025 volumes. The consistent EPS beat pattern reflects strong cost discipline and favorable mix, suggesting the EPS bar is typically set conservatively.

Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Guidance was raised at the midpoint on the Q1 2026 call (April 30) and has not been formally revised since. Management tone is constructively confident, with specific sequential improvement guided for BLS book-to-bill in Q2 and Early Development streamlining on track for completion by end of Q2.

Source: Q1 2026 Earnings Call Transcript (April 30, 2026). No post-earnings guidance revisions via 8-K or conference have been identified since the Q1 print.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates for Q2 2026 and FY 2026 have been remarkably stable since the Q1 print — revenue and EPS consensus are essentially flat vs. the post-Q1 baseline, suggesting the street has fully absorbed the guidance raise without adding incremental cushion. This leaves the bar achievable but not sandbagged.

Estimates have barely moved since the Q1 print — all key metrics are within ±0.1% of the post-earnings baseline. This stability reflects a well-anchored consensus that has absorbed the guidance raise without adding further upside. The BLS TTM book-to-bill estimate has actually ticked up +3.2% since the Q1 print, suggesting the street is incrementally more constructive on BLS backlog conversion.

Source: Visible Alpha Consensus and Actuals Data. Baseline as of approximately May 7, 2026 (5 trading days post Q1 2026 earnings). Current consensus as of July 29, 2026.

5. Stock Performance

Key Takeaway: LH has outperformed XLV by ~+5.7pp since the Q1 2026 earnings date (LH +19.6% vs. XLV +13.9%), driven primarily by the beat-and-raise print and PAMA delay relief. The re-rating has been sentiment- and multiple-driven rather than estimate-driven, as consensus has barely moved — suggesting the stock's gains are durable only if Q2 delivers.

LH vs. XLV (Health Care ETF) — Indexed to 100 at Q1 2026 Earnings Date (April 30, 2026). Source: Stock Price Data (Yahoo Finance).

• LH: $256.80 → $307.15 (+19.6% since Apr 30, 2026 earnings date)
• XLV (Health Care ETF): $145.99 → $166.24 (+13.9% over same period)
• LH vs. XLV outperformance: +5.7pp since Q1 earnings
• Key events marked: CEO 10b5-1 sale (May 13), Quest Diagnostics Q2 earnings (July 23 — strong read-through), Dividend declared (July 10)
• Sector ETF used: XLV (Health Care Select Sector SPDR ETF) — appropriate for LH's diagnostics/health services sub-sector

6. Peer Commentaries — Read-Through for Q2 2026

Key Takeaway: Peer commentary from the last 60 days is broadly constructive for LH's Q2 print. Quest Diagnostics' Q2 2026 results (reported July 23) are the most direct and positive read-through — 10% organic revenue growth and raised guidance signal robust diagnostics demand. CRO peers (Charles River, ICON) confirm stabilizing biopharma demand and improving book-to-bill trends, supportive of LH's BLS Central Labs outlook.

Note: Only commentary about Q2 2026 (the current reporting quarter) or forward-looking commentary made after Q1 2026 earnings is included below. Prior-quarter results commentary has been excluded.

Quest Diagnostics (DGX) — Q2 2026 Earnings (Reported July 23, 2026)

Relevance: Highest-relevance read-through. DGX is LH's closest direct peer in U.S. clinical diagnostics. DGX's Q2 2026 results are the most timely and direct signal for LH's Diagnostics segment.

• Strong organic volume growth: DGX reported 10.1% organic revenue growth in Diagnostic Information Services for Q2 2026, with total requisition volume up 13.1% (organic +13%). Excluding the Corewell and Fresenius relationships, organic volume grew +4.1% — a clean read on underlying market demand. This is a positive read-through for LH's Diagnostics organic volume, which consensus pegs at ~3.9% for Q2.
• Broad-based clinical demand: DGX cited broad demand from physicians, hospitals, and consumers, with physician channel delivering high single-digit revenue growth and hospital channel growing double digits. Advanced diagnostics (cardiometabolic, autoimmune, brain health, oncology, women's health) all grew double digits. This aligns with LH's specialty testing momentum in neurology, oncology, and autoimmune.
• Alzheimer's / brain health testing: DGX reported Alzheimer's testing growing in the "high double digits," with Elevance now reimbursing for tau 217 biomarker. This is a direct positive read-through for LH's neurology segment, which management cited as growing double digits driven by Alzheimer's testing on the Q1 call.
• ACA exchange impact: DGX still anticipates a 30bps revenue impact for FY 2026 from ACA exchange subsidy expiration, consistent with LH's own 30bps estimate. DGX noted enrollment is down ~21% but the revenue impact is modest due to mix (sicker patients remaining, more tests per requisition). This confirms LH's ACA assumption is reasonable and not a downside risk.
• PAMA advocacy: DGX noted the CMS data collection process ends July 30 (same day as LH's earnings), with results expected late September. DGX continues to advocate for the Results Act (bipartisan, 115+ co-sponsors). If not passed, DGX will push for another delay. This is consistent with LH's messaging and confirms PAMA is a 2027 issue, not a 2026 headwind.
• Guidance raised: DGX raised FY 2026 revenue guidance to $11.95B–$12.05B (+8.3%–9.2%) and adjusted EPS to $11.05–$11.25. Operating margin expected to expand for the full year. This is a positive industry-level signal for LH's own guidance trajectory.
• Pricing: Revenue per requisition was down 2.8% due to Corewell/Fresenius mix, but up +2.9% excluding those relationships, driven by tests per requisition improvement (now >4.5 tests/req vs. 3.5–4 pre-COVID). This supports LH's mix-shift narrative toward higher-value specialty testing.

Neogenomics (NEO) — Q2 2026 Earnings (Reported July 28, 2026)

Relevance: Moderate relevance. NEO is a specialty oncology diagnostics company. Read-through is most relevant for LH's oncology and MRD testing strategy.

• Strong clinical volume growth: NEO reported 11% total revenue growth in Q2 2026, with clinical business growing 14%. NGS revenue grew 26% YoY, with large NGS panels growing >20%. This confirms robust demand for high-value specialty oncology testing — a positive read-through for LH's oncology double-digit growth narrative.
• AUP (average unit price) growth: NEO's AUP grew 12% in Q2, driven by RCM initiatives and mix shift toward high-value testing. This supports LH's revenue-per-accession improvement thesis as specialty mix increases.
• Pharma/non-clinical business weak: NEO's pharma revenue declined 26% YoY in Q2, though bookings hit all-time highs. NEO views the pharma business as "near the bottom." This is a mild negative read-through for LH's BLS Early Development segment, though LH's Central Labs business is more insulated.
• MRD market commentary: NEO's Radar Street MRD product has two Medicare-reimbursed indications (HPV-negative head/neck, subset of breast cancers), with additional submissions pending. NEO expects a "meaningful uptick" in MRD in 2027. This is consistent with LH's own MRD positioning (Plasma Detect ID/Genome) and confirms the market is still in early innings.
• Guidance raised: NEO raised FY 2026 revenue guidance to $802M–$806M and adjusted EBITDA to $56M–$58M (+30%+ YoY). Positive for specialty diagnostics sentiment broadly.

Charles River Laboratories (CRL) — Q1 2026 Earnings (May 7, 2026) + Conference Commentary (June 2–3, 2026)

Relevance: Moderate relevance for LH's BLS segment, particularly Central Labs and Early Development. CRL is a leading CRO/preclinical services company with significant overlap in biopharma customer base.

• Biopharma demand stabilizing: CRL stated at both the William Blair (June 2) and Jefferies (June 3) conferences that "demand has been stabilizing" with "good signs of improvement." Biotech net bookings in the last two quarters were at their highest level in over two years. Global biopharma clients have largely completed restructuring and pipeline reprioritization. This is a positive read-through for LH's BLS Central Labs, which serves similar biopharma customers.
• Proposal volume up high single digits: CRL noted proposal volume is up high single digits for both biotech and pharma segments, with KPI trends indicating a return to DSA growth. This supports LH's expectation of sequential BLS book-to-bill improvement in Q2.
• Early development still soft: CRL's CRADL business (early-stage biotech vivarium) has seen lagging demand, linked to constrained early-phase/seed funding. CRL divested certain European early discovery assets. This is a mild negative read-through for LH's Early Development segment, though LH has already guided for ~flat Early Development revenue for FY 2026 and is streamlining the business.
• AI as structural tailwind: CRL cited a Deloitte survey showing ~60% of biopharma R&D executives expect AI investments to increase IND approvals. This aligns with LH's own messaging that AI will accelerate clinical trial timelines and increase reliance on global lab expertise — a tailwind for BLS.
• Q2 2026 outlook: CRL reaffirmed FY 2026 guidance at the Jefferies conference (June 3), expecting revenue decline of 1.5%–0.5% and non-GAAP EPS of $10.80–$11.30. CRL guided for "clear sight to ~500bps margin improvement" in 2H 2026. Neutral for LH — CRL's challenges are specific to its preclinical/early discovery mix, not Central Labs.

ICON plc (ICLR) — Q4 2025 Earnings (May 28, 2026) + Q1 2026 Earnings (June 24, 2026)

Relevance: Moderate relevance for LH's BLS Central Labs segment. ICON is a large CRO with a growing central laboratory business and overlapping biopharma customer base.

• Strong bookings momentum: ICON reported Q1 2026 gross bookings of $3.3B (up 22% YoY), net book-to-bill of 1.42x, and cancellations in line with improved Q4 2025 levels. Win rates remained strong in both large pharma and biotech. This is a positive read-through for LH's BLS Central Labs book-to-bill recovery in Q2.
• Central Labs specifically highlighted: ICON won a Central Labs partnership from a top-5 pharma customer in Q1 2026 where they previously had limited labs business. ICON is expanding its central laboratory facility in Singapore. ICON noted that RFPs for development solutions businesses (including central labs, specialty labs) are increasing, with ballpark RFPs up from 12% to 17% of total. This confirms growing demand for central lab services — a direct positive read-through for LH's Central Labs.
• Biotech funding constructive: ICON noted biotech funding remains constructive with ongoing activity in larger follow-on capital raises supporting late-stage clinical programs. Large pharma continues to invest in clinical pipelines. This supports LH's BLS demand outlook.
• Q2 2026 demand broadly comparable: ICON's CEO stated "I see no reason why performance shouldn't be broadly in line" for Q2 vs. Q1, with Q2 expected to be "a very strong quarter for signing." EBITDA margin for Q2 guided to ~16%. This is a positive read-through for LH's BLS Q2 book-to-bill recovery.
• Phase III skew increasing: ICON noted the number of Phase III trials in Q2 awards was substantially higher (averaging 29%–45% of awards). Phase III trials are typically larger and longer-duration, which is positive for Central Labs revenue visibility and backlog quality.
• Pricing environment: ICON described pricing as a "knife fight every quarter" but noted no underlying change in the pricing environment. Neutral for LH's BLS margins.

7. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is Quest Diagnostics' strong Q2 2026 print (July 23), which provides the most direct and timely positive read-through for LH's Diagnostics segment heading into tomorrow's report. PAMA delay through 2026 remains the key regulatory relief, and the September 10 Investor Day signals management confidence in the long-term story.

• July 23, 2026 — Quest Diagnostics (DGX) Q2 2026 Earnings Beat & Raise: DGX reported 10.2% revenue growth and 19%+ adjusted EPS growth, raising FY 2026 guidance. Broad-based clinical demand, Alzheimer's testing in high double-digit growth, and ACA impact tracking to 30bps estimate. Implication: Most direct positive read-through for LH's Diagnostics segment; confirms robust underlying demand environment heading into LH's Q2 print.
• July 10, 2026 — Labcorp Declares $0.72/Share Quarterly Cash Dividend: Board approved regular quarterly dividend. Implication: Signals continued financial health and capital return commitment; no change to capital allocation strategy.
• June 30, 2026 — Labcorp Schedules Q2 2026 Earnings Release for July 30, 2026: Formal announcement of earnings date. No pre-announcement or guidance revision included. Implication: Absence of a pre-announcement is a mild positive signal — no need to warn on results.
• May 27, 2026 — Labcorp to Present at Jefferies Global Healthcare Conference: Management presented at the Jefferies conference. No material guidance revision was issued. Implication: Consistent with management's confident tone post-Q1; no negative pre-announcement.
• April 30, 2026 — Q1 2026 Beat & Raise / Investor Day Announced: LH beat on both revenue and adjusted EPS, raised FY 2026 guidance midpoints, and announced an Investor Day for September 10, 2026 in New York City. Implication: Sets a constructive tone for Q2; Investor Day signals management confidence in long-term trajectory.
• April 30, 2026 — myLabCorp AI-Powered Mobile App Launch (May 2026): Management announced the launch of the myLabCorp mobile app in May 2026, featuring an AI assistant for personalized health insights, appointment scheduling, and test results. Implication: Supports consumer health (LabCorp OnDemand) growth trajectory; reinforces AI integration narrative.
• April 30, 2026 — MRD Portfolio Expansion (Plasma Detect ID & Genome): LH launched Plasma Detect ID (breast and lung cancer) and Plasma Detect Genome (colon cancer) in Q1 2026. Management views MRD as a large, underpenetrated market. Implication: Oncology specialty testing growth driver; supports double-digit oncology growth narrative.
• April 30, 2026 — PAMA Delay Confirmed Through December 31, 2026: PAMA implementation pushed to 2027; AMA data survey just beginning with hospital participation levels unknown. Implication: Removes a key 2026 headwind; broader hospital reporting would reduce LH's PAMA impact given its position as a high-quality, lower-cost provider.
• April 30, 2026 — New Strategic Central Labs Facility Announced: LH announced plans to build a new >500,000 sq ft laboratory and production facility to support long-term Central Labs growth, with construction expected to begin later in 2026. Implication: Reflects management confidence in sustained BLS Central Labs demand; CapEx ~4% of revenue for FY 2026.
• April 30, 2026 — CRUSH Initiative (CMS Fraud/Waste/Abuse): CMS's CRUSH initiative is a new regulatory variable. LH supports the initiative's goals but has advocated for avoiding unintended consequences that could impede Medicare patient access to medically necessary lab testing. Implication: Regulatory wildcard to monitor; management does not expect material near-term impact.

8. Insider Transaction Activity

Key Takeaway: All insider transactions since Q1 earnings are 10b5-1 plan-driven sales and RSU-related activity — no open-market discretionary buys or sells. The CEO's 10b5-1 sale in May (5,903 shares) is the largest transaction by value but is pre-planned and not a discretionary signal. Nothing in the insider activity stands out as a meaningful directional signal for Q2.

All transactions are 10b5-1 plan-driven or RSU-related (tax withholding). There are no open-market discretionary buys or sells in the period since Q1 2026 earnings. The absence of discretionary insider buying is not unusual given the stock's +19.6% rally since April 30. No insider activity provides a meaningful directional signal for Q2 2026 results.

Source: Insider Transaction Data (SEC Form 4 filings). Transactions shown are those filed between April 30, 2026 and July 29, 2026.